• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by MeiraGTx Holdings plc

    3/13/25 4:30:51 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGTX alert in real time by email
    S-8 1 tmb-20250312xs8.htm S-8

    ​

    ​

    As filed with the Securities and Exchange Commission on March 13, 2025

    Registration No. 333-

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM S-8

    ​

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933


    MeiraGTx Holdings plc

    (Exact name of registrant as specified in its charter)


    ​

    Cayman Islands

     

    98-1448305

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    ​

    450 East 29th Street, 14th Floor

    New York, NY

     

    10016

    (Address of Principal Executive Offices)

     

    (Zip Code)

    ​

    ​

    MeiraGTx Holdings plc 2018 Incentive Award Plan

    (Full title of the plan)


    Alexandria Forbes, Ph.D.

    President and Chief Executive Officer

    MeiraGTx, LLC

    450 East 29th Street, 14th Floor

    New York, NY 10016

    ​

    (Name and address of agent for service)

    ​

    (646) 860-7985

    (Telephone number, including area code, of agent for service)


    Copies to:

    Peter N. Handrinos

    Keith L. Halverstam

    Latham & Watkins LLP

    200 Clarendon Street

    Boston, Massachusetts 02116

    (617) 948-6000


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    ​

    Large accelerated filer

     

    ☐

     

    Accelerated filer

     

    ☐

     

     

     

     

     

     

     

    Non-accelerated filer

     

    ☒

     

    Smaller reporting company

     

    ☒

     

     

     

     

     

     

     

    ​

    ​

    ​

     

    Emerging growth company

     

    ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

    ​

    ​

    ​


    EXPLANATORY NOTE

    ​

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 8,412,566 ordinary shares, nominal value $0.00003881 per share (“Ordinary Shares”) of MeiraGTx Holdings plc (the “Registrant”) that may be issuable under the MeiraGTx Holdings plc 2018 Incentive Award Plan (the “2018 Plan”). Registration Statements of the Registrant on Form S-8 relating to the 2018 Plan are effective.

    ​

    INCORPORATION BY REFERENCE OF CONTENTS OF
    REGISTRATION STATEMENTS ON FORM S-8

    ​

    The contents of the Registration Statements on Form S-8 (File Nos. 333-257164 and 333-225535), including any amendments thereto, filed with the Securities and Exchange Commission, relating to the 2018 Plan, are incorporated by reference herein.

    ​

    PART II

    ​

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ​

    Item 8.   Exhibits.

    ​

    ​

    ​

    ​

    Exhibit No.

        

    Description

    ​

    ​

    ​

    4.1

     

    Amended and Restated Memorandum and Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38520) filed August 7, 2019).

    ​

    ​

    ​

    4.2

     

    Shareholder Agreement (incorporated by reference to Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-38520) filed March 11, 2020).

    ​

     

     

    5.1*

    ​

    Opinion of Walkers, counsel to the Registrant.

    ​

     

     

    23.1*

    ​

    Consent of Ernst & Young LLP.

    ​

     

     

    23.2*

    ​

    Consent of Walkers (included in Exhibit 5.1).

    ​

     

     

    24.1*

     

    Power of Attorney (included on signature page hereto).

    ​

    ​

    ​

    99.1

     

    MeiraGTx Holdings plc 2018 Incentive Award Plan (incorporated by reference to Exhibit 10.2 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (Reg. No. 333-224914) filed on May 29, 2018).

    ​

    ​

    ​

    107*

    ​

    Filing Fee Table

    ​


    *  Filed herewith.

    ​


    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 13th day of March 2025.

    ​

    ​

    MEIRAGTX HOLDINGS PLC

    ​

    ​

    ​

    By:

    /s/ Alexandria Forbes, Ph.D.

    ​

    ​

    Alexandria Forbes, Ph.D.

    ​

    ​

    President and Chief Executive Officer

    (principal executive officer)

    ​

    SIGNATURES AND POWER OF ATTORNEY

    ​

    We, the undersigned officers and directors of MeiraGTx Holdings plc, hereby severally constitute and appoint Alexandria Forbes, Ph.D., Richard Giroux and Robert J. Wollin, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    ​

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.

    ​

    ​

    ​

    ​

    ​

    ​

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Alexandria Forbes, Ph.D.

     

    President, Chief Executive Officer and Director
    (principal executive officer)

     

    March 13, 2025

    Alexandria Forbes, Ph.D.

     

     

     

     

     

     

     

     

     

    /s/ Richard Giroux

     

    Chief Financial Officer and Chief Operating Officer

    (principal financial officer and principal accounting officer) and MeiraGTx Holdings plc’s authorized representative in the United States

     

    March 13, 2025

    Richard Giroux

     

     

     

     

     

     

     

     

     

    /s/ Keith R. Harris, Ph.D.

     

    Chairman of the Board of Directors and Director

     

    March 13, 2025

    Keith R. Harris, Ph.D.

     

     

     

     

    ​

    ​

    ​

    ​

    ​

    /s/ Ellen Hukkelhoven Ph.D.

     

    Director

     

    ​

    ​

    ​

    ​

    ​

    March 13, 2025

    Ellen Hukkelhoven, Ph.D.

     

     

     

     

    ​

    ​

    ​

    ​

    ​

    /s/ Lord Mendoza

     

    Director

     

    March 13, 2025

    Lord Mendoza

     

     

     

     

     

     

     

     

     

    /s/ Nicole Seligman

     

    Director

     

    March 13, 2025

    Nicole Seligman

     

     

     

     

    ​

    ​

    ​

    ​

    ​


    /s/ Thomas E. Shenk, Ph.D.

     

    Director

     

    March 13, 2025

    Thomas E. Shenk, Ph.D.

     

     

     

     

    ​

    ​

    ​

    ​

    ​

    /s/ Debra Yu, M.D.

     

    Director

     

    March 13, 2025

    Debra Yu, M.D.

     

     

     

     

    ​


    Get the next $MGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGTX

    DatePrice TargetRatingAnalyst
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

      Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

      7/31/24 6:30:53 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by MeiraGTx Holdings plc

      10-Q - MeiraGTx Holdings plc (0001735438) (Filer)

      5/13/25 8:09:19 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MeiraGTx Holdings plc (0001735438) (Filer)

      5/13/25 8:05:14 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Holdings plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - MeiraGTx Holdings plc (0001735438) (Filer)

      5/9/25 8:13:51 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Financials

    Live finance-specific insights

    See more
    • MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

      Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity, reaching the normal range in bilaterally treated participants by 2 months and persisting through the Month 12 assessmentAcross assessments, greater improvements observed in bilaterally treated participants compared to those treated unilaterally Early long-term follow-up data suggest durability of improvement to at least 3 years post-treatmentAAV2-hAQP1 appears safe and well tolerated at each dose te

      6/27/23 7:30:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023

      LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for

      6/22/23 4:01:00 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

      Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoin

      12/13/22 7:30:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Landsdowne Labs Names Bryan Laulicht CEO

      Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

      6/13/23 9:05:00 AM ET
      $MGTX
      $AMAG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Pharmaceuticals
    • MeiraGTx Appoints Debra Yu, MD to Board of Directors

      LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen

      4/27/22 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

      SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      11/12/24 9:40:33 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

      SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      10/18/24 4:47:58 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

      SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

      8/14/24 7:21:27 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      8/14/24 6:54:38 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MeiraGTx Reports First Quarter 2025 Financial and Operational Results

      -  Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson's disease -  Gained alignment with FDA on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential BL

      5/13/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

      -  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease -  RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the t

      5/9/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

      -  Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  MeiraGTx and Hologen have created the first neuro-AI clinical drug development company to transform the discovery and development of therapies targeting CNS circuitry in neurodegenerative and neuropsychiatric disorders -  Announced positive data from randomized, double blind, sham-controlled clinical bridging study of AAV-GAD for the treatment of Parkinson's disease demonst

      3/13/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & COO Giroux Richard sold $144,000 worth of Ordinary Shares (24,000 units at $6.00), decreasing direct ownership by 3% to 882,494 units (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/22/25 8:54:27 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT & CEO Forbes Alexandria sold $253,650 worth of Ordinary Shares (47,500 units at $5.34), decreasing direct ownership by 3% to 1,408,983 units (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/8/25 9:05:58 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO & COO Giroux Richard

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      4/7/25 9:05:31 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care